Kaku, K <br/><br/>
Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study.  [electronic resource] 

 -  Diabetes, obesity & metabolism  Dec 2015 
 - 1198-201 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12555  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Combined Modality Therapy--adverse effects<br/>Diabetes Mellitus, Type 2--blood<br/>Diet, Diabetic<br/>Dipeptidyl-Peptidase IV Inhibitors--adverse effects<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Resistance<br/>Drug Therapy, Combination--adverse effects<br/>Exercise<br/>Glycated Hemoglobin--analysis<br/>Humans<br/>Hyperglycemia--prevention & control<br/>Hypoglycemic Agents--administration & dosage<br/>Japan<br/>Pioglitazone<br/>Piperidines--adverse effects<br/>Thiazolidinediones--administration & dosage<br/>Uracil--adverse effects